Thyroid Medication Recalled Due to Potential Overpotency

Vitruvias Therapeutics has recalled one lot of Thyroid Tablets, USP 30 mg, after testing indicated the product might contain a higher dose than labeled. Consumption of superpotent tablets can lead to hyperthyroidism, posing health risks such as rapid heart rate and chest pain, particularly for elderly individuals, pregnant women, and infants. Patients are advised to consult their healthcare provider before discontinuing the medication.